Jun 30,2022

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022.

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Psychosocial Effects of the Loop Open-Source Automated Insulin Delivery System

This study examined the psychosocial impact of Loop, an open-source automated insulin dosing system that has emerged from the diabetes technology “Do-It-Yourself” (DIY) movement.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Analysis of “Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes”

This study analyzes the article by Laffell et al examining the accuracy and performance of a seventh-generation “G7” continuous glucose monitor (CGM) system in participants with type 1 diabetes aged 2 to 17 years.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Insulin Pump-Associated Adverse Events in a Brazilian Reference Center for the Treatment of Diabetes Mellitus: Proposal for a Taxonomy of Device Failures in Adults, Adolescents, and Children

The study aims to propose a taxonomy based on the prevalent AEs experienced by patients from a reference diabetes mellitus (DM) center in Brazil using different continuous subcutaneous insulin infusion (CSII) devices.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Insulin Requirements for Basal and Auto-Correction Insulin Delivery in Advanced Hybrid Closed-Loop System: 4193 Days’ Real-World Data of Children in Two Different Age Groups

The MiniMed 780G system delivers micro boluses to adjust basal insulin and delivers auto-correction boluses to meet insulin needs when micro bolus increases are insufficient. Through analysis of MiniMed 780G data, this study investigates the variations in insulin requirements throughout the day.

CLINICAL STUDY

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Safety and Functional Integrity of CGM Sensors When Used During Radiologic Procedures Under High Exposure Conditions

The study investigates wearable components of the Abbott Diabetes Care FreeStyle Libre® (continuous glucose monitoring [CGM 1), FreeStyle Libre® 2 (CGM 2), and FreeStyle Libre® 3 (CGM 3) systems in simulated diagnostic radiologic procedures.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Brighter’s interim CEO Erik Lissner takes permanent role as the company CEO

Brighter AB (Publ) (“Brighter”) announced today that the company has agreed on a contract with Erik Lissner regarding his permanent role as CEO at Brighter. The agreed contract takes effect today, June 30, 2022.

View Analyst & Ambassador Comments
Go to original news
Jun 30,2022

Dexcom Schedules Second Quarter 2022 Earnings Release and Conference Call for July 28, 2022 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022.

View Analyst & Ambassador Comments
Go to original news
Jul 06,2022

Rimidi Expands Team by 86%, Grows Revenue by 100% in First Half of 2022

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today that the company has expanded its employee base by 86% and seen a 100% growth in revenue, accompanied by an enlargement of its Atlanta headquarters.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES